News | Industry

Opinion

We must learn the lessons from Priadel

The discontinuation of Priadel shows we need a tougher regulatory environment to prevent firms making commercial decisions that put vulnerable patients at risk.…

Published: 23 October 2020

News

NHS England boss accuses Priadel manufacturer of using COVID-19 to ‘price-gouge’ British taxpayers

The chief executive of NHS England has accused the manufacturer of a first-line medication for bipolar disorder of “trying to jack the prices of a long-standing medicine”.…

Published: 6 October 2020

Feature

The COVID-19 vaccines being backed by the UK and when we might get them

The UK government has ordered 340 million doses of COVID-19 vaccines from several manufacturers, with the hope that at least one will prove successful in large clinical trials over the next few months. However, there are no guarantees and some of the strategies are not without their challenges.…

Published: 1 October 2020

News

Health bodies make ‘urgent’ call to Matt Hancock to intervene in the proposed withdrawal of bipolar drug

The health secretary, Matt Hancock, has been urged to “personally intervene” so that bipolar drug Priadel remains available in the UK with an appropriate pricing structure.…

Published: 17 September 2020

Feature

Beyond antibiotics: harnessing bacteria’s natural predators

With antibiotic resistance set to cost 10 million lives per year by 2050, there is a renaissance of interest in the potential of bacteriophages to be the next generation of bacteria killers.…

Published: 10 September 2020

Opinion

Why ‘epidrugs’ will be the next major focus for precision medicine

It is not just our genes that dictate how our bodies cope with disease and respond to drugs — by identifying the modifications to our DNA strands, and the histone proteins that regulate gene expression, we can uncover a whole new direction for diagnostic biomarkers, therapeutic biomarkers and …

Published: 9 September 2020

Feature

Roger M. Perlmutter: ‘The free flow of scientific talent in and out of the UK is incredibly important’

Roger M. Perlmutter is the executive vice president of Merck Sharp & Dohme, and president of MSD Research Laboratories. On a visit to London, he caught up with Gino Martini, chief scientist at the Royal Pharmaceutical Society, for a chat about the future of pharmaceutical research and …

Published: 20 August 2020

Opinion

Evidence shows the antibiotics market is failing, but here is how it can be revived

A core group of pharmaceutical companies are making progress in tackling the spread of antimicrobial resistance, but change is not happening at the scale needed to radically impact the threat from drug resistance.…

Published: 19 August 2020

Feature

Drugs in space: the pharmacy orbiting the Earth

Researchers are busy developing pharmaceutical solutions for astronauts, but that extraterrestrial research could also have implications for how medicines are delivered on Earth.…

Published: 9 July 2020

Feature

The role of a scientific advisor and how to become one

Industry pharmacist Neel Bhatt gives his tips and advice on how to break into the sector as a scientific advisor.…

Published: 6 July 2020